Nesiritide for the treatment of heart failure
Please note that following on from information provided to NICE by the company in June 2012, the appraisal of Nesiritide for the treatment of heart failure [ID384] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 384
- Referral date:
- 01 October 2000
- Topic area
- Cardiovascular, Therapeutic procedures
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- TBC
- 1st appraisal committee meeting::
- TBC
- 2nd appraisal committee meeting:
- TBC
Project Team
- Assessment Group / Evidence Review Group:
- Peninsula Technology Assessment Group, University of Exeter
- Communications manager:
- Phil Ranson
- Executive Lead:
- Peter Littlejohns
- Project manager:
- Emily Marschke
- Technical Lead:
- TBC
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in June 2012, the appraisal of Nesiritide for the treatment of heart failure [ID384] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 10 February 2004 | Date of Information Meeting for Consultees added. |
| 14 January 2005 | Technology Appraisal Project Manager changed. |
| 17 March 2005 | Schedule updated. |
| 6 April 2005 | Date of information meeting for Consultees amended. |
| 27 May 2005 | Provisional schedule updated. |
| 25 August 2006 | This topic was transferred to the Single technology appraisal (STA) process as part of the Institute's 12th wave work programme. |
For further information on our processes and methods, please see our CHTE processes and methods manual